EcoDrugPlus

Proteasome 26s Subunit, Non-Atpase 7

Ensembl ID : ENSOMEG00000009303
Gene Symbol: PSMD7
3 Cross references
235 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 8

Ensembl ID : ENSOMEG00000001269
Gene Symbol: PSMD8
3 Cross references
211 Possible Orthologues:

Proteasome Subunit Beta 11

Ensembl ID : ENSOMEG00000013392
Gene Symbol: PSMB11
3 Cross references
169 Possible Orthologues:

Proteasome Subunit Beta Type-11-Like

Ensembl ID : ENSOMEG00000005285
Gene Symbol: LOC112150731
3 Cross references
159 Possible Orthologues:

Proteasome Subunit Beta Type-5-Like

Ensembl ID : ENSOMEG00000013456
Gene Symbol: LOC112147624
3 Cross references
203 Possible Orthologues:

Proteasome Subunit Beta Type-7-Like

Ensembl ID : ENSOMEG00000004851
Gene Symbol: LOC112144185
3 Cross references
171 Possible Orthologues:

Proteasome Subunit Beta Type-8-Like

Ensembl ID : ENSOMEG00000017126
Gene Symbol: LOC112137399
3 Cross references
214 Possible Orthologues:

Proteasome Subunit Beta Type-8-Like

Ensembl ID : ENSOMEG00000020286
Gene Symbol: LOC112140153
3 Cross references
214 Possible Orthologues:

Proteasome Subunit Beta Type-9

Ensembl ID : ENSOMEG00000017066
Gene Symbol: LOC112136178
3 Cross references
201 Possible Orthologues:

Protein Arginine Methyltransferase 5

Ensembl ID : ENSOMEG00000013235
Gene Symbol: PRMT5
3 Cross references
198 Possible Orthologues:

Protein Farnesyltransferase Subunit Beta-Like

Ensembl ID : ENSOMEG00000021960
Gene Symbol: LOC112158416
3 Cross references
209 Possible Orthologues:

Protein Kinase C Beta

Ensembl ID : ENSOMEG00000020661
Gene Symbol: PRKCB
2 Cross references
207 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).